Coronavirus Disease 2019 (COVID-19) Vaccination for Children : Position Statement of Indian Academy of Pediatrics Advisory Committee on Vaccination and Immunization Practices
JUSTIFICATION: Data generated after the first wave has revealed that some children with coronavirus 19 (COVID-19) can become seriously ill. Multi-inflammatory syndrome in children (MIS-C) and long COVID cause significant morbidity in children. Prolonged school closures and quarantine have played havoc with the psychosocial health of children. Many countries in the world have issued emergency use authorisation (EUA) of selected Covid-19 vaccines for use in children. In India, a Subject Expert Committee (SEC) has recommended the use of Covaxin (Bharat Biotech) for children from the ages of 2-18 years. The recommendation has been given to the Drugs Controller General of India (DCGI) for final approval.
OBJECTIVE: To provide an evidence-based document to guide the pediatricians on the recommendation to administer COVID vaccines to children, as and when they are available for use.
PROCESS: Formulation of key questions was done by the committee, followed by review of literature on epidemiology and burden of Covid-19 in children, review of the studies on COVID vaccines in children, and the IAP stand on Covid-19 vaccination in children. The available data was discussed in the ACVIP focused WhatsApp group followed by an online meeting on 24 October, 2021, wherein the document was discussed in detail and finalized.
RECOMMENDATIONS: The IAP supports the Government of India's decision to extend the COVID-19 vaccination program to children between 2-18 years of age. Children with high-risk conditions may be immunized on a priority basis. The IAP and its members should be a partner with the Government of India, in the implementation of this program and the surveillance that is necessary following the roll-out.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Indian pediatrics - 59(2022), 1 vom: 15. Jan., Seite 51-57 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kasi, Srinivas G [VerfasserIn] |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 28.01.2022 Date Revised 29.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM334636604 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334636604 | ||
| 003 | DE-627 | ||
| 005 | 20231225224129.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1115.xml |
| 035 | |a (DE-627)NLM334636604 | ||
| 035 | |a (NLM)34927603 | ||
| 035 | |a (PII)S097475591600381 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kasi, Srinivas G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Coronavirus Disease 2019 (COVID-19) Vaccination for Children |b Position Statement of Indian Academy of Pediatrics Advisory Committee on Vaccination and Immunization Practices |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.01.2022 | ||
| 500 | |a Date Revised 29.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a JUSTIFICATION: Data generated after the first wave has revealed that some children with coronavirus 19 (COVID-19) can become seriously ill. Multi-inflammatory syndrome in children (MIS-C) and long COVID cause significant morbidity in children. Prolonged school closures and quarantine have played havoc with the psychosocial health of children. Many countries in the world have issued emergency use authorisation (EUA) of selected Covid-19 vaccines for use in children. In India, a Subject Expert Committee (SEC) has recommended the use of Covaxin (Bharat Biotech) for children from the ages of 2-18 years. The recommendation has been given to the Drugs Controller General of India (DCGI) for final approval | ||
| 520 | |a OBJECTIVE: To provide an evidence-based document to guide the pediatricians on the recommendation to administer COVID vaccines to children, as and when they are available for use | ||
| 520 | |a PROCESS: Formulation of key questions was done by the committee, followed by review of literature on epidemiology and burden of Covid-19 in children, review of the studies on COVID vaccines in children, and the IAP stand on Covid-19 vaccination in children. The available data was discussed in the ACVIP focused WhatsApp group followed by an online meeting on 24 October, 2021, wherein the document was discussed in detail and finalized | ||
| 520 | |a RECOMMENDATIONS: The IAP supports the Government of India's decision to extend the COVID-19 vaccination program to children between 2-18 years of age. Children with high-risk conditions may be immunized on a priority basis. The IAP and its members should be a partner with the Government of India, in the implementation of this program and the surveillance that is necessary following the roll-out | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Dhir, Shashi Kant |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Abhay |e verfasserin |4 aut | |
| 700 | 1 | |a Shivananda, S |e verfasserin |4 aut | |
| 700 | 1 | |a Verma, Sanjay |e verfasserin |4 aut | |
| 700 | 1 | |a Marathe, S |e verfasserin |4 aut | |
| 700 | 1 | |a Chatterjee, Kripasindhu |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwalla, Sunil |e verfasserin |4 aut | |
| 700 | 1 | |a Srirampur, Sanjay |e verfasserin |4 aut | |
| 700 | 1 | |a Kalyani, Srinivas |e verfasserin |4 aut | |
| 700 | 1 | |a Pemde, Harish K |e verfasserin |4 aut | |
| 700 | 1 | |a Balasubramanian, S |e verfasserin |4 aut | |
| 700 | 1 | |a Basavaraja, G V |e verfasserin |4 aut | |
| 700 | 1 | |a Parekh, Bakul J |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Remesh |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Piyush |e verfasserin |4 aut | |
| 700 | 0 | |a For Advisory Committee on Vaccines and Immunization Practices (ACVIP), Indian Academy of Pediatrics |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian pediatrics |d 1964 |g 59(2022), 1 vom: 15. Jan., Seite 51-57 |w (DE-627)NLM000375144 |x 0974-7559 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2022 |g number:1 |g day:15 |g month:01 |g pages:51-57 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2022 |e 1 |b 15 |c 01 |h 51-57 | ||